IACS-010759 in Advanced Cancers
IACS-010759 in Advanced Cancers
This phase I trial studies the side effects and best dose of oxidative phosphorylation
 inhibitor IACS-010759 (IACS-010759) in treating patients with lymphoma that has come back
 (relapsed) or does not respond to treatment (refractory) or solid tumors that have spread to
 other places in the body (advanced/metastatic) or cannot be removed by surgery
 (unresectable). IACS-010759 may stop the growth of cancer or tumor cells by blocking some of
 the enzymes needed for cell growth.
PRIMARY OBJECTIVES:

 I. To determine the safety and tolerability of IACS-010759, the maximum tolerated dose (MTD)
 and recommended phase 2 dose (RP2D) in subjects with any advanced solid tumor and lymphoma.

 SECONDARY OBJECTIVES:

 I. To evaluate IACS-010759 pharmacokinetics and preliminary antitumor activity (including
 overall response rate and duration of response).

 EXPLORATORY OBJECTIVES:

 I. To evaluate pharmacodynamic and exploratory predictive biomarkers of activity of
 IACS-010759.

 OUTLINE: This is a dose-escalation study.

 INDUCTION PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 orally (PO)
 once daily (QD) on days 1-7 of cycle 1 in the absence of disease progression or unacceptable
 toxicity.

 MAINTENANCE PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on
 days 8 and 15 of cycle 1 and then on days 1, 8, and 15 of subsequent cycles. Cycles repeat
 every 21 days in the absence of disease progression or unacceptable toxicity.

 After completion of study treatment, patients are followed up at 30 days and then every 3-6
 months for up to 2 years.
Inclusion Criteria:

 -  Non-pregnant.

 -  Subjects must have histologically confirmed malignancy that is metastatic or
 unresectable and for which there is no available therapy likely to convey clinical
 benefit.

 -  Subjects must have received at least one line of systemic therapy in the
 advanced/metastatic setting. Subjects with diseases without known effective options
 are also eligible. a) Subjects with relapsed and/or refractory lymphoma must have had
 at least 2 prior lines of systemic therapy and are not candidates for high dose
 therapy/autologous stem cell transplant.

 -  Subjects must have evaluable disease for the dose escalation, and measurable disease
 for the dose expansion.

 -  Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of
 0 to 1.

 -  Subjects must have a life expectancy >= 12 weeks.

 -  Absolute neutrophil count >= 1,500/mcL.

 -  Hemoglobin >= 9 g/dL.

 -  Platelets >= 100,000/mcL.

 -  Total bilirubin =< 1.5 x the institutional upper limit of normal (ULN).

 -  Aspartate transaminase (AST) serum glutamic oxaloacetic transaminase (SGOT)/alanine
 transaminase (ALT) serum glutamic pyruvic transaminase (SGPT) =< 2.5 x institutional
 ULN or =< 5 x institutional ULN in the presence of liver metastases.

 -  Creatinine clearance >= 45 mL/min/1.73 m^2 for subjects with creatinine levels above
 institutional normal.

 -  Women of childbearing potential (WOCBP) must agree to use an adequate method of
 contraception during the study and until 3 months after the last treatment. Males must
 be surgically or biologically sterile or agree to use an adequate method of
 contraception during the study until 3 months after the last treatment. Adequate
 methods of contraception include: total abstinence when this is in line with the
 preferred and usual lifestyle of the subject; periodic abstinence (e.g., calendar,
 ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable
 methods of contraception.

 -  Female sterilization (have had surgical bilateral oophorectomy with or without
 hysterectomy) or tubal ligation at least six weeks before taking study treatment. In
 case of oophorectomy alone, only when the reproductive status of the woman has been
 confirmed by follow up hormone level assessment; male sterilization (at least 6 months
 prior to screening). For female subjects on the study, the vasectomized male partner
 should be the sole partner for that subject.

 -  Combination of any of the two following (a+b or a+c or b+c): a) use of oral, injected
 or implanted hormonal methods of contraception or other forms of hormonal
 contraception that have comparable efficacy (failure rate < 1%), for example hormone
 vaginal ring or transdermal hormone contraception; b) placement of an intrauterine
 device (IUD) or intrauterine system (IUS); c) barrier methods of contraception: condom
 or occlusive cap (diaphragm or cervical/vault caps) with spermicidal
 foam/gel/film/cream/ vaginal suppository. In case of use of oral contraception, women
 should have been stable on the same pill before taking study treatment.

 -  Oral contraceptives are allowed but should be used in conjunction with a barrier
 method of contraception due to unknown effect of drug-drug interaction. Women are
 considered post-menopausal and not of child bearing potential if they have had 12
 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g.
 age appropriate, history of vasomotor symptoms) or have had surgical bilateral
 oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago.
 In the case of oophorectomy alone, only when the reproductive status of the woman has
 been confirmed by follow up hormone level assessment is she considered not of child
 bearing potential.

 -  Subjects must have disease that can be safely biopsied (for RP2D biopsy expansion
 cohort only), and agree to undergo a pretreatment and on-treatment biopsy.

 -  Subjects with brain metastases must have completed treatment, either surgery or
 radiation, 4 weeks or longer prior to screening. A brain magnetic resonance imaging
 (MRI) demonstrating there is no current evidence of progressive brain metastases is
 required in subjects with previous brain metastasis. Patients with breast tissue
 expanders may have brain computerized tomography (CT) for assessment.

 -  Subjects must not be on full dose oral anticoagulation such as warfarin. Low dose
 warfarin and prophylactic as well as therapeutic low molecular weight heparin are
 allowable.

 -  Subjects who enroll in the triple-negative breast cancer (TNBC) dose expansion cohort
 should adhere to the American Society for Clinical Pathology (ASCP)/College of
 American Pathologists (CAP) guidelines for the definition of TNBC.

 -  Subjects must have the ability to understand and the willingness to sign a written
 informed consent document.

 Exclusion Criteria:

 -  Subjects who have had chemotherapy or radiotherapy within 3 weeks (4 weeks for
 immunotherapy; 6 weeks for nitrosoureas or mitomycin C) prior to starting the study
 agent.

 -  Subjects with active brain metastases.

 -  Subjects may not be receiving any other investigational agents or have participated in
 any other clinical trial involving another investigational agent for treatment of
 advanced solid tumors or lymphoma within 3 weeks prior to cycle 1, day 1 of the study.

 -  Subjects who had major surgery or radiation therapy within 4 weeks of the first dose
 of study drug, except for palliative radiotherapy to a limited field, such as for the
 treatment of bone pain or a focally painful tumor mass.

 -  Subjects with a history of allergic reactions attributed to compounds of similar
 chemical or biologic composition to IACS-010759.

 -  Subjects receiving metformin or other agents known to increase risk of lactic
 acidosis.

 -  Subjects who previously received IACS-010759 or oxidative phosphorylation (OXPHOS)
 inhibitors.

 -  Subjects with uncontrolled intercurrent illness including, but not limited to ongoing
 or active serious bacterial, fungal or viral infection or psychiatric illness/social
 situations that would limit compliance with study requirements.

 -  Subjects with a history of significant cardiac disease including: congestive heart
 failure requiring therapy; history of myocardial infarction (MI), angina pectoris,
 coronary artery bypass graft (CABG) within 6 months prior to starting study treatment;
 clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete
 left bundle branch block, high-grade atrioventricular (AV) block (e.g., bifascicular
 block, Mobitz type II and third degree AV block); left ventricular ejection fraction
 (LVEF) < 50% evaluated by echocardiogram (ECHO) or multigated acquisition scan (MUGA);
 increased Fridericia's correction formula (QTcF) (> 450 for men and > 470 for women).

 -  Women who are breast-feeding or pregnant as evidenced by positive serum or urine
 pregnancy test performed within 72 hours of first dosing. (Pregnant women are excluded
 from this study because it is not known whether IACS-010759 has the potential for
 teratogenic or abortifacient effects. Because there is an unknown but potential risk
 for adverse events in nursing infants secondary to treatment of the mother with
 IACS-010759 breastfeeding should be discontinued if the mother is treated with
 IACS-010759.)

 -  Subjects with significant gastrointestinal abnormalities that may affect absorption
 (e.g., gastric bypass, short gut syndrome).

 -  Subjects with known human immunodeficiency virus (HIV), acute chronic hepatitis B
 virus surface antigen (HBsAg) or hepatitis C virus. (HIV-positive subjects are
 ineligible because of the potential for pharmacokinetic interactions of antiviral
 therapy with IACS-010759.)

 -  Lactic acid levels > 2 mmol/L and/or serum pH < 7.35 at baseline.

 -  Subjects with other active malignancy in the past 3 years with the exception of
 adequately treated basal cell or squamous cell carcinoma of the skin, in situ cervical
 cancer, or another early stage cancer that in the discretion of the investigator(s) is
 currently in complete remission.

 -  Subjects with >= Common Terminology Criteria for Adverse Events (CTCAE) grade 2
 toxicity (except alopecia) due to prior cancer therapy.

 -  Subjects with any concomitant disease or condition that, in the clinical judgment of
 the treating physician, is likely to prevent the subject from complying with any
 aspect of the protocol or that may put the subject at unacceptable risk.

 -  Subjects with >= grade 1 peripheral neuropathy at screening.